Chemical structure of molecule LYC-55716 Cintirorgon

oral ROR_ nuclear receptor agonist

450 mg BID, phase I/II, cancer

from change in MoA of ROR_ antagonist + opt.

Journal of Medicinal Chemistry


The Lycera ROR gamma agonist, cintirorgon (LYC-55716), is a first-in-class phase 1b clinical candidate for cancer immunotherapy (in combination with pembrolizumab in NSCLC). ROR gamma antagonists have been extensively…

 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.